Katelyn Byrne, Ph.D.

  • Assistant Professor of Cell, Developmental and Cancer Biology, School of Medicine
  • Member, Brenden-Colson Center for Pancreatic Care
  • Member, OHSU Knight Cancer Institute, School of Medicine

Biography

The Byrne Lab aims to understand the underlying immunobiology regulating therapeutic sensitivity in pancreatic cancer. Our research focuses on interrogating mechanisms of bridging innate and adaptive immunity that drive tumor rejection in preclinical models of cancer, and revealing correlates of response for patients receiving immunotherapy.

Education and training

    • B.A., 2007, Boston University
    • Ph.D., 2013, Dartmouth College
  • Fellowship

    • American Cancer Society Post-doctoral Fellowship
    • Senior Parker Fellow, Parker Institute for Cancer Immunotherapy

Memberships and associations:

  • American Association for Cancer Research (AACR)
  • American Association of Immunologists (AAI)

Areas of interest

  • pancreatic cancer
  • immunotherapy
  • tumor microenvironment

Publications

Selected publications

  • Byrne KT*, Betts CB*, Mick R*, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O’Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH. T cell inflammation in the tumor microenvironment after neoadjuvant agonist CD40 antibody in patients with resectable pancreatic cancer.
  • Yang F, He Z, Duan H, Zhang D, Li J, Yang H, Dorsey JF, Zou W, Nabavizadeh SA, Bagley SJ, Abdullah K, Brem S, Zhang L, Xu X, Byrne KT, Vonderheide RH, Gong Y, Fan Y. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nature Communications, 12(1):3424, 2021.
  • Roehle K, Qiang K, Ventre K, Heid D, Ali LR, Lenehan P, Heckler M, Crowley SJ, Stump CT, Ro G, Godicelj A, Bhuuiyan MA, Yang A, Quiles del Rey M, Biary T, Luoma AM, Bruck PT, Tegethoff JF, Nopper SL, Li H, Byrne KT, Pelletier M, Wucherpfennig KW, Stanger BZ, Akin JJ, Mancias JD, Agudo J, Dougan M, Dougan SK. Destruction of MHC Class I negative tumors through T cell dependent reprogramming of mononuclear phagocytes. Science Translational Medicine, 13(594):eabf5058, 20
  • O’Hara MH, O’Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher GA, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch L, Xu J, Samuel T, Karakunnel J, Fairchild J, Bucktrout S, LaVallee TM, Selinsky C, Till JE, Carpenter EL, Alanio C, Byrne KT, Chen RO, Trifan OC, Dugan U, Horak C, Hubbard-Lacy VM, Wherry EJ, Ibrahim R, Vonderheide RH. Agonistic CD40 monoclonal antibody APX005M and chemotherapy with or without nivolumab for the treatment of
  • Huffman AP, Lin JH, Kim SI, Byrne KT, Vonderheide RH. CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity. JCI Insight, 5(10):e137263, 2020.
  • Morrison AH, Diamond MS, Hay CA, Byrne KT*, Vonderheide RH*. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. Proceedings of the National Academy of Sciences, 117(14):8022-8031, 2020.
  • Hay CA, Sor R, Flower AJ, Clendenin C, Byrne KT. Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma. Journal of Visualized Experiments, (153), e60479, doi:10.3791/60497, 2019.
  • Markosyan N, Li J, Sun YH, Richman LP, Lin JH, Yan F, Quinones L, Sela Y, Yamazoe T, Gordon N, Tobias JW, Byrne KT, Rech AJ, Fitzgerald GA, Stanger BZ, Vonderheide RH. Tumor cell intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). Journal of Clinical Investigation, 4(130):3594-3609, 2019.
  • Li J*, Byrne KT*, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Coussens LM, Wherry EJ, Vonderheide RH, Stanger BZ. Tumor cell-intrinsic factor underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity, 49(1):178-193, 2018.
  • Malik BT, Byrne KT, Vella JL, Zhang P, Shabenah TB, Steinberg SM, Molodtsov AK, Bowers JS, Angeles CV, Paulos CM, Huang YH, Turk MJ. Resident memory T cells in skin mediate durable immunity to melanoma. Science Immunology, 2(10), 2017.

Publications

  • {{ pub.journalAssociation.journal.name.text[0].value }}